Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with
advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment:
a randomized, open-label, multicenter, phase 2 study